Ataluren

Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.

Price Not Available 50 mg Ataluren Supplier Page

Catalog Number	T1805
Alternative Name(s)	PTC124
Research Area	Membrane transporter/Ion channel\|\|\|Autophagy
Molecular Formula	C15H9FN2O3
CAS#	775304-57-9
SMILES	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F
Size	50 mg
Supplier Page	https://www.targetmol.com/compound/Ataluren
Additional Information	https://www.targetmol.com/datasheet/T1805